The effect of hydroxy safflower yellow A on coronary heart disease through Bcl‑2/Bax and PPAR‑γ

Zhou, Dayan; Qu, Zongjie; Wang, Hao; Su, Yong; Wang, Yazhu; Zhang, Weiwei; Wang, Zhe; Xu, Qiang

doi:10.3892/etm.2017.5414

Cited by 18 publications

(14 citation statements)

References 25 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exposing neutrophils or macrophages to HMGB1 can lead to enhanced NF-κB signaling pathway and pro-inflammatory cytokine expression (Park et al, 2004). Interestingly, SY can improve inflammatory response and exert effect on inflammatory factors, like TNF-α, IL-1(IL-1β), and IL-6 (Zhou et al, 2018;Du et al, 2019; Figure 3). Furthermore, SY can inhibit the activation of the NF-κB signaling pathway by suppressing IκBα phosphorylation and cell nucleus translocation of p65 (Li et al, 2013; Figure 3).…”

Section: Safflower Yellow Inhibits the Hmgb1-tlr4-nf-κb Signaling Pathwaymentioning

confidence: 99%

The Repression of the HMGB1-TLR4-NF-κB Signaling Pathway by Safflower Yellow May Improve Spinal Cord Injury

2021

View full text Add to dashboard Cite

Spinal cord injury (SCI) often results in abnormal sensory and motor functions. Current interventions for SCI in the clinical setting are not effective partly due to the complexity concerning its pathophysiological mechanism. In the wake of SCI, considerable inflammatory cells assemble around the injured area that induces a series of inflammatory reactions and aggravates tissue lesions, thereby affecting the recovery of the damaged nerve tissue. Therefore, the inhibition of inflammatory responses can improve the repair of the injured spinal cord tissue. Safflower Yellow (SY) is the main active ingredient of Carthamus tinctorius. SY has anti-inflammatory effect, as it can inhibit IκBα phosphorylation to impede the NF-κB signaling pathway and p53 nuclear translocation. Besides, SY can limit the release of pro-inflammatory factors, which in turn may alleviate secondary SCI and prevent further complications. In this report, we analyze the pathophysiological mechanism of SCI, the role of inflammatory responses, and how SY interferes with the HMGB1-TLR-4-NF-κB signaling pathway to attenuate inflammatory responses in SCI.

show abstract

Section: Safflower Yellow Inhibits the Hmgb1-tlr4-nf-κb Signaling Pathwaymentioning

confidence: 99%

The Repression of the HMGB1-TLR4-NF-κB Signaling Pathway by Safflower Yellow May Improve Spinal Cord Injury

2021

View full text Add to dashboard Cite

show abstract

“…Safflower is an extract of Crocus sativus L. and is commonly used in the treatment of CVD. Clinical studies have shown that safflower has antioxidant and antiarrhythmic effects, as well as protective effects on damaged myocardium [ 152 – 154 ]. Thus, safflower is an antioxidant with potential for the prevention and treatment of heart failure.…”

Section: Application Of Antioxidant Natural Drugs For Cardiovasculmentioning

confidence: 99%

Natural Drugs as a Treatment Strategy for Cardiovascular Disease through the Regulation of Oxidative Stress

Chang

Zhang

et al. 2020

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Oxidative stress (OS) refers to the physiological imbalance between oxidative and antioxidative processes leading to increased oxidation, which then results in the inflammatory infiltration of neutrophils, increased protease secretion, and the production of a large number of oxidative intermediates. Oxidative stress is considered an important factor in the pathogenesis of cardiovascular disease (CVD). At present, active components of Chinese herbal medicines (CHMs) have been widely used for the treatment of CVD, including coronary heart disease and hypertension. Since the discovery of artemisinin for the treatment of malaria by Nobel laureate Youyou Tu, the therapeutic effects of active components of CHM on various diseases have been widely investigated by the medical community. It has been found that various active CHM components can regulate oxidative stress and the circulatory system, including ginsenoside, astragaloside, and resveratrol. This paper reviews advances in the use of active CHM components that modulate oxidative stress, suggesting potential drugs for the treatment of various CVDs.

show abstract

“…In our study, we found that safflower yellow could dilate blood vessels, thereby lowering blood pressure, expanding coronary arteries, relieving myocardial ischaemia, and decreasing mental fatigue. This may be related to the fact that this drug can inhibit inflammation and oxidative stress, relieve pulmonary hypertension, reduce hypoxic pulmonary artery reconstruction, reverse right ventricular hypertrophy and remodelling, inhibit myocardial cell apoptosis, and improve cardiac ejection fraction [16, 17, 25], ultimately protecting and restoring cardiac function in patients with COPD and relieving heart palpitations and mental fatigue.…”

Section: Discussionmentioning

confidence: 99%

The Effects of Safflower Yellow on Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Clinical Trial

Kang

Wang

et al. 2019

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objectives To evaluate the efficacy of safflower yellow in the acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods In a prospective, randomized, controlled trial, 127 patients who met the inclusion criteria were enrolled and were randomly divided into two groups. The control group included 64 patients treated according to the global strategy for diagnosis, management, and prevention of COPD (www.goldcopd.org, updated 2011). The intervention group included 63 patients who received intravenous infusions of safflower yellow (100 mg of safflower yellow dissolved in 250 ml 0.9% saline) once daily for 14 consecutive days in addition to standard diagnosis and treatment. The difference in the average length of the hospital stay between the two groups of patients was determined. The follow-up period was 28 days; the differences in symptoms, clinical indicators, and 28-day mortality in the two groups were compared. Statistical analysis was conducted using SPSS 22.0 software to determine whether there were statistically significant differences (P <0.05) between groups. Results There were no statistically significant differences between the intervention group and the control group in changes in secondary indicators. There were no statistically significant differences in the 28-day mortality or in the survival curves of the two groups (P=0.496 and P=0.075, respectively). Safflower yellow treatment of AECOPD may relieve the patient's clinical symptoms, such as dyspnoea, shorten the average length of hospital stay (P=0.006, respectively), and decrease the duration of mechanical ventilation. Conclusion Safflower yellow in the treatment of AECOPD has a degree of clinical value. This trial is registered under the identifier ChiCTR-IPR-17014176.

show abstract

The effect of hydroxy safflower yellow A on coronary heart disease through Bcl‑2/Bax and PPAR‑γ

Cited by 18 publications

References 25 publications

The Repression of the HMGB1-TLR4-NF-κB Signaling Pathway by Safflower Yellow May Improve Spinal Cord Injury

The Repression of the HMGB1-TLR4-NF-κB Signaling Pathway by Safflower Yellow May Improve Spinal Cord Injury

Natural Drugs as a Treatment Strategy for Cardiovascular Disease through the Regulation of Oxidative Stress

The Effects of Safflower Yellow on Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Clinical Trial

Contact Info

Product

Resources

About